Home › Trials › NCT07532863
Clinical trial Recruiting at 1 site Observational Ages 40 to 70

Cardiovascular risk profile in people newly diagnosed with type 2 diabetes in Southeast Asia

Official title: A Retrospective Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus Participants in Southeast Asia

Run by Novo Nordisk A/S · NCT07532863 · Data updated 2026-11-12

This project will see how cardiovascular risk is distributed among people aged 40–69 who were newly diagnosed with type 2 diabetes and started treatment in Southeast Asia using medical records from the year before and the first year after diagnosis.

More Diabetes Mellitus, Type 2 trials

Quick facts

Study typeObservational
Ages40 Years to 70 Years
SexAll
Enrollment400 (estimated)
SponsorNovo Nordisk A/S
Industry-sponsored
Locations6 sites (Tangerang, Banten and 5 other locations)
StatusRecruiting
StartedMarch 13, 2026
Main results expectedMarch 27, 2027
Study endsMarch 27, 2027
Registry record updatedJuly 28, 2026
Trial IDNCT07532863 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are people aged 40–69 who were newly diagnosed with type 2 diabetes and started anti-hyperglycemic treatment between January 1, 2022 and December 31, 2023 at one of the participating Southeast Asian centers and who had at least one visit about 12 months after diagnosis.

Probably not a fit

People with type 1 or gestational diabetes, those who had anti-hyperglycemic drugs before their first recorded diagnosis, pregnant women, people with pre-existing atherosclerotic cardiovascular disease, or those who died or were lost to follow-up within 12 months after diagnosis will be excluded and are unlikely to benefit from inclusion.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective chart-review using clinical records from participating centers across five Southeast Asian countries to characterize cardiovascular disease risk in people newly diagnosed with type 2 diabetes. Eligible participants are aged 40–69 and initiated anti-hyperglycemic therapy between January 1, 2022 and December 31, 2023. Researchers will use data from roughly the year before diagnosis and the first year after diagnosis to describe risk factors and the distribution of CVD risk, excluding people with prior atherosclerotic CVD or prior glucose-lowering therapy. No treatments are given as part of the project; data are analyzed to describe patterns and inform care planning in the region.

Why it matters

Potential benefit: If successful, the findings could help clinicians and health systems in Southeast Asia identify common cardiovascular risk patterns in newly diagnosed type 2 diabetes and target earlier prevention.

How similar studies have gone: Retrospective and registry studies in other regions have described cardiovascular risk in people with type 2 diabetes, but large multi-country datasets focused on Southeast Asia remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Aged greater than equal to (≥) 40 and less than (\<) 70 years
* Male or female
* Newly diagnosed with T2DM and initiated on anti-hyperglycemic treatment between 1 January 2022 and 31 December 2023

Exclusion Criteria:

* If any exclusion criterion is met, the participant will be excluded from the study.
* T1DM or gestational diabetes
* Prescribed with any anti-hyperglycemic medications before first diagnosis of T2DM
* Pregnant women
* With pre-existing atherosclerotic CVD including coronary heart disease, stroke, transient ischemic attack, or peripheral artery disease
* Died within 12 months after first diagnosis of T2DM
* Lost to follow-up i.e., no visit 12 months (± 3 months) after first diagnosis of T2DM

Where it's running

  • Novo Nordisk Investigational Site
    Singapore, Singapore     Recruiting
  • Siloam Hospitals Lippo Village
    Tangerang, Banten, Indonesia     Not yet recruiting
  • Siloam Hospitals Surabaya
    Surabaya, East Java, Indonesia     Enrolling by invitation
  • University Malaya Medical Centre
    Lembah Pantai, Kuala Lumpur, Malaysia     Enrolling by invitation
  • National Heart Institute
    Kuala Lumpur, Malaysia     Not yet recruiting
  • The Medical City Ortigas
    Pasig, National Capital Region, Philippines     Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Diabetes Mellitus, Type 2 185Novo Nordisk A/S 70
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.